Cargando…
Safety and efficacy of classical complement pathway inhibition with sutimlimab in chronic immune thrombocytopenia
Chronic/refractory immune thrombocytopenia (ITP) is a rare and pathophysiologically heterogeneous disorder with variable responsiveness to available treatments. Sutimlimab, a first-in-class humanized monoclonal anti-C1s IgG4 antibody, selectively inhibits the classical pathway. This phase 1 study (N...
Autores principales: | Broome, Catherine M., Röth, Alexander, Kuter, David J., Scully, Marie, Smith, Roy, Wang, Jennifer, Reuter, Caroline, Hobbs, William, Daak, Ahmed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The American Society of Hematology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10027504/ https://www.ncbi.nlm.nih.gov/pubmed/35973190 http://dx.doi.org/10.1182/bloodadvances.2021006864 |
Ejemplares similares
-
COVID-19 vaccination in patients with immune thrombocytopenia
por: Visser, Chantal, et al.
Publicado: (2022) -
Complement gene variant effect on relapse of complement-mediated thrombotic microangiopathy after eculizumab cessation
por: Acosta-Medina, Aldo A., et al.
Publicado: (2022) -
Expanding the genetic spectrum of TUBB1-related thrombocytopenia
por: Palma-Barqueros, Verónica, et al.
Publicado: (2021) -
Ribosome dysfunction underlies SLFN14-related thrombocytopenia
por: Ver Donck, Fabienne, et al.
Publicado: (2023) -
Cost-effectiveness of eltrombopag vs intravenous immunoglobulin for the perioperative management of immune thrombocytopenia
por: Kaur, Manraj N., et al.
Publicado: (2022)